Sanford Laboratories For Innovative Medicines
EIN: 873910792 · San Diego, CA · NTEE: A05
Is Sanford Laboratories For Innovative Medicines Legit?
Insufficient Data
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
About Sanford Laboratories For Innovative Medicines
Sanford Laboratories For Innovative Medicines (EIN: 873910792) is a nonprofit organization based in San Diego, CA, classified under NTEE code A05. The organization reported total revenue of $12.8M and total assets of $20.2M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Sanford Laboratories For Innovative Medicines's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Sanford Laboratories For Innovative Medicines is a large nonprofit that has been operating for 4 years, with 2 years of IRS 990 filings on record (2022–2023). Revenue has grown at a compound annual rate of 526.3%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $12.5M |
| Total Expenses | $3.9M |
| Surplus / Deficit | +$8.6M |
| Total Assets | $26.1M |
| Total Liabilities | $15.5M |
| Net Assets | $10.6M |
| Operating Margin | 68.6% |
| Debt-to-Asset Ratio | 59.4% |
| Months of Reserves | 79.6 months |
Financial Health Grade: A
In 2023, Sanford Laboratories For Innovative Medicines reported a surplus of $8.6M with revenue exceeding expenses, holds 79.6 months of operating reserves (strong position), has a debt-to-asset ratio of 59.4% (high leverage).
Financial Trends
Over 2 years of filings (2022–2023), Sanford Laboratories For Innovative Medicines's revenue has grown at a compound annual growth rate (CAGR) of 526.3%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +526.3% | +24754.5% | +117.2% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1800 |
| IRS Ruling Date | 2022 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Analysis Pending
AI enrichment for Sanford Laboratories For Innovative Medicines has not yet been completed. Basic IRS 990 data is shown below. Check back later for a full transparency report including a Mission Score, spending breakdown, executive compensation analysis, and red flags assessment.
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Sanford Laboratories For Innovative Medicines with a Mission Score of 0 out of 100 (Very Poor). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $8.6M, with revenue exceeding expenses.
- Debt-to-asset ratio: 59.4%.
Frequently Asked Questions about Sanford Laboratories For Innovative Medicines
Is Sanford Laboratories For Innovative Medicines a legitimate charity?
Based on AI analysis of IRS 990 filings, Sanford Laboratories For Innovative Medicines (EIN: 873910792) insufficient data. 0 red flags identified, 0 strengths noted.
How does Sanford Laboratories For Innovative Medicines spend its money?
Detailed spending breakdown data is not yet available for Sanford Laboratories For Innovative Medicines. Check back for updated IRS 990 analysis.
Are donations to Sanford Laboratories For Innovative Medicines tax-deductible?
Sanford Laboratories For Innovative Medicines is registered as a tax-exempt nonprofit (EIN: 873910792). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Filing History
IRS 990 filing history for Sanford Laboratories For Innovative Medicines showing financial trends over 2 years of public records:
Over 2 years of IRS 990 filings (2022–2023), Sanford Laboratories For Innovative Medicines's revenue has grown by 526.3%, moving from $2.0M to $12.5M. Total assets increased by 117.2% over the same period, from $12.0M to $26.1M. Total functional expenses rose by 24754.5%, from $16K to $3.9M. In its most recent filing year (2023), Sanford Laboratories For Innovative Medicines reported a surplus of $8.6M, with revenue exceeding expenses. The organization holds $15.5M in liabilities against $26.1M in assets (debt-to-asset ratio: 59.4%), resulting in net assets of $10.6M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $12.5M | $3.9M | $26.1M | $15.5M | — | View 990 |
| 2022 | $2.0M | $16K | $12.0M | $10.0M | — | — |
Data Sources and Methodology
This transparency report for Sanford Laboratories For Innovative Medicines is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.